- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced clear cell variant renal cell carcinoma in combination with nivolumab
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 715KB)
Cabozantinib – March 2024
Cabozantinib (clear cell RCC): Tablet 20 mg, Tablet 40 mg; Cabometyx®
Last updated
30 May 2025